13 July 2021
EMA/CHMP/397322/2021
Human Medicines Division

Committee for medicinal products for human use (CHMP)

PROM[1] minutes for the meeting on 12 July 2021

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

12 July 2021, 09:00–16:00, virtual meeting / room 08-A

Disclaimers

Some of the information contained in this document is considered commercially confidential or sensitive and therefore not disclosed.

Of note, agendas and minutes are working documents primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

[1] The CHMP PReparatory and Organisational Matters (PROM) is a meeting to discuss CHMP organisational matters and other topics in preparation for the CHMP Plenary meeting. It is a virtual meeting, which usually takes place on Monday before the CHMP Plenary meeting. CHMP members, working party chairs and national experts together with EMA staff are participating in this forum. Depending on the nature of the issue and availability of documents and experts some PROM topics can be discussed at the CHMP Plenary.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Agenda and Minutes

1.1. Welcome and declarations of interest of members, alternates and experts

1.2. Adoption of agenda

CHMP PROM agenda for 12 July 2021 meeting

The CHMP adopted PROM Agenda for 10 May 2021 meeting.

1.3. Adoption of the minutes

CHMP PROM Minutes of 12 July 2021 meeting will be adopted at the July 2021 CHMP plenary.

2. Non therapeutic-area-specific working parties

2.1. Patients and Consumers Working Party (PCWP) Healthcare Professionals Working Party (HCPWP)

PCWP: Co-chair: Kaisa Immonen Co-chair: Juan Garcia Burgos (EMA)

HCPWP: Co-chair: Ulrich Jaeger Co-chair: Juan Garcia Burgos (EMA)

2.1.1. Minutes

- Minutes from joint PCWP/HCPWP meeting held by Webex on 1-2 June 2021

Action: For information

CHMP noted the minutes.

2.2. Biologics Working Party (BWP)

Chairs: Sol Ruiz/Nanna Aaby Kruse

2.2.1. Agenda and Minutes

- Final minutes for BWP meeting held by WebEx on 10 May 2021
- Draft agenda for BWP meeting to be held by WebEx on 10 May 2021

Action: For information

CHMP noted the agenda and the minutes.

2.3. Quality Working Party (QWP)

Chair: Blanka Hirschlerova

2.3.1. Minutes

- Final minutes from QWP Core Team meeting held by teleconference on 16 June 2021

Action: For information

CHMP noted the minutes.

2.3.2. Guideline on quality documentation for medicinal products when used with a medical device (EMEA/CHMP/QWP/BWP/259165/2019)

Public consultation on the draft guideline: June-August 2019; Revised guideline adopted by QWP, BWP and CAT: April 2021

Action: For adoption

CHMP adopted the Guideline on quality documentation for medicinal products when used with a medical device with no further comments.

2.3.3. Interim feedback from QWP to the EC request to evaluate the impact of the removal of titanium dioxide from the list of authorised food additives on medicinal products

On 6 May 2021, the European Food Safety Authority (EFSA) published its opinion on the safety of food additive titanium dioxide. On 17 May 2021, the European Commission (EC) requested the European Medicines Agency (EMA) to provide an analysis with the aim to define the technical purpose of titanium dioxide in medicinal products. Interim feedback from QWP to the EC request to evaluate the impact of the removal of titanium dioxide from the list of authorised food additives on medicinal products.

Action: For adoption

CHMP adopted the Interim feedback from QWP to the EC request to evaluate the impact of the removal of titanium dioxide from the list of authorised food additives on medicinal products with no further comments.

2.3.4. Change in nomination of member in the QWP

New Croatian member to replace Koraljka Mestrovic.

Action: For endorsement

CHMP endorsed Ivica Malnar as new member of the QWP representing Croatia.

2.4. Safety Working Party (SWP)

Chairs: Jan Willem Van der Laan/Susanne Brendler-Schwaab

2.4.1. Minutes

- Final minutes for SWP/EFSA meeting dedicated to TiO2 held by teleconference on 10 May 2021
- Final minutes for SWP meeting held by teleconference on 17 May 2021

Action: For information

CHMP noted the minutes.

2.4.2. CMDh question to SWP regarding methodology for setting limits for multiple genotoxic impurities including nitrosamines

The CMDh has requested that the SWP (where appropriate with consultation of the QWP) - propose a methodology for setting limits for genotoxic impurities when both one or multiple nitrosamine impurities and other genotoxic impurities are present.

Action: For adoption

CHMP adopted the CMDh question to SWP regarding methodology for setting limits for multiple genotoxic impurities including nitrosamines.

2.4.3. CMDh request on the AI for the nitrosamine N-Nitrosodi-n-propylamine (NDPA)

The CMDh has requested that the SWP provide a position on the AI for NDPA.

Action: For adoption

CHMP adopted the CMDh request on the AI for the nitrosamine N-Nitrosodi-n-propylamine (NDPA) with no further comments.

2.4.4. SWP response to HMPC request for feedback on public statement on the use of herbal medicinal products containing estragole

SWP response to HMPC on final public statement on the use of herbal medicinal products containing estragole.

Action: For adoption

CHMP adopted the SWP response to HMPC request for feedback on public statement on the use of herbal medicinal products containing estragole with no further comments.

2.5. Biosimilar Medicinal Product Working Party (BMWP)

No topics

2.6. Biostatistics Working Party (BSWP)

Chair: Kit Roes

2.6.1. Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development (EMA/CHMP/138502/2017)

Reflection paper statistical methodology for the comparative assessment of quality attributes in drug development and high-level overview of how the comments received were taken into consideration. Follow up from discussion on June 2021 PROM meeting.

Action: For adoption

CHMP adopted the Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development.

2.7. Modelling and Simulation Working Party (MSWP)

Chairs: Kristin Karlsson/Flora Musuamba Tshinanu

2.7.1. Agenda and Minutes

- Draft agenda of MSWP meeting held virtually via Webex on 30 June 2021
- Table of Decisions of MSWP meeting held virtually via Webex on 30 June 2021

Action: For information

CHMP noted the agenda and the table of decisions.

2.8. Pharmacogenomics Working Party (PGWP)

No topics

2.9. Pharmacokinetics Working Party (PKWP)

Chair: Carolien Versantvoort

2.9.1. Minutes

- Final minutes of PKWP meeting held via Webex on 01 July 2021

Action: For information

CHMP noted the minutes.

2.9.2. PKWP response to CMDh request on Megestrol acetate 40 mg/ml oral suspension

Questions have been raised in regard to the interpretation of CPMP/EWP/QWP/1401/98 Rev. 1/ Corr ** (chapter 4.1.4 Fasting or fed conditions) in terms of the general study requirements of micronised suspension generic applications.

Action: For adoption

CHMP adopted the PKWP response to CMDh request on Megestrol acetate.

2.9.3. PKWP response to CMDh request on pirfenidone tablet formulations

PKWP response to CMDh request on pirfenidone tablet formulations over bioequivalence requirements.

Action: For adoption

CHMP did not adopt the PKWP response to CMDh request on pirfenidone tablet formulations over bioequivalence requirements.

2.9.4. CMDh request for PKWP input on bioequivalence waiver for an oily parenteral (i.m.) solution

CMDh request for PKWP input on bioequivalence waiver for an oily parenteral (i.m.) solution to clarify if viscosity and/or what other in vitro comparative data are needed to demonstrate

comparable physicochemical characteristics of oily solutions too, sufficient to support a biowaiver.

Action: For adoption

CHMP adopted the CMDh request for PKWP input on bioequivalence waiver for an oily parenteral (i.m.) solution with no further comments.

2.9.5. PKWP request to CHMP to draft a Q&A on expectations for how to conduct bootstrapping to calculate the 90% CI of f2

PKWP proposes to clarify how to conduct the f2 CI bootstrapping and how to report this as related issues have arisen in a number of procedures. The input of QWP and BSWP is also sought.

Action: For adoption

CHMP adopted the request for PKWP to draft a Q&A on expectations for how to conduct bootstrapping to calculate the 90% CI of f2 with the input from QWP and BSWP.

3. Therapeutic-area-specific working parties and SAGs

3.1. Blood Products Working Party (BPWP)

No topics

3.2. Central Nervous System Working Party (CNSWP)

No topics

3.3. Cardiovascular Working Party (CVSWP)

No topics

3.4. Infectious Diseases Working Party (IDWP)

Chair(s): Vacant

3.4.1. Call for nomination of IDWP Chair

The mandate of the Chair Maria Jesús Fernández Cortizo expired in November 2020. The election is scheduled at the July CHMP Plenary meeting.

Nominations received.

Action: For information

The CHMP noted the nomination(s) received for the IDWP chair election.

3.5. Oncology Working Party (ONCWP)

Chairs: Sinan B. Sarac/Paolo Foggi

3.5.1. Minutes

- Final minutes of ONCWP meeting held via Webex on 10 June 2021

Action: For information

CHMP noted the minutes.

3.6. Rheumatology/Immunology Working Party (RIWP)

No topics

3.7. Vaccines Working Party (VWP)

No topics

3.8. Scientific Advisory Groups (SAGs)

3.8.1. SAG re-nominations

Draft list of SAG candidates.

Action: For adoption

CHMP was presented with the preliminary draft list of candidates for SAGs (SAG Oncology, SAG Cardiovascular, SAG Neurology, SAG Vaccines and SAG Infectious diseases) membership nominations.

4. Drafting groups

4.1. Excipients Drafting Group

No topics

4.2. Gastroenterology Drafting Group (GDG)

No topics

4.3. Geriatric Expert Group (GEG)

No topics

4.4. Radiopharmaceuticals Drafting Group (RadDG)

No topics

4.5. Respiratory Drafting Group (RDG)

No topics

5. Harmonisation and consistency groups

5.1. International Council on Harmonisation (ICH)

5.1.1. Nomination of experts for ICH groups

- Appointment of one expert for the ICH M4Q(R2) Common Technical Document on Quality Guideline

Expressions of interest received.

Action: For adoption

CHMP appointed A.J. (Ton) van der Stappen (CBG-MEB) as experts for the ICH M4Q(R2) Common Technical Document on Quality Guideline. They will be supported by a multidisciplinary group of experts/EMA staff with the goal of enabling the delivery of IT solutions related to this work. It was also agreed that René Thürmer (BfArM) could participate in this group in the role of QWP liaison.

5.1.2. ICH E19 Safety data collection - update

The draft ICH E19 guideline explores under what circumstances a targeted approach to safety data collection in some late-stage pre-marketing or post-marketing studies would be appropriate and how to implement such an approach.

The draft guidance has been released for public consultation in 2019. Since then, the dedicated ICH working group has discussed and negotiated amendments to the draft guideline. The main objective of this update is to present the updated ICH E19 Guideline and to highlight the changes implemented to address the concerns expressed by European regulators during the public consultation.

Action: For discussion

CHMP noted the update on the revision on ICH E19 Safety data collection and supported the revised guidance document.

5.1.3. ICH Q13 Continuous Manufacturing of Drug Substances and Drug Products

Step2b - draft guidance ICH Q13 Continuous Manufacturing of Drug Substances and Drug Products to be adopted for public consultation until 22 December 2021

Action: For adoption

CHMP adopted the Step2b - draft guidance ICH Q13 Continuous Manufacturing of Drug Substances and Drug Products for public consultation until 22 December 2021 with no further comments.

5.1.4. ICH report from meeting in Incheon, Republic of Korea (May-June 2021)

- Presentation

Action: For information

- Report

Action: For adoption

CHMP adopted the ICH report and the underlying actions from the virtual ICH meeting held May-June 2021 with no further comments.

5.2. Guideline Consistency Group (GCG)

No topics

5.3. Summary of product characteristics Advisory Group

No topics

6. Joint groups and collaboration with other Scientific committees

6.1. Joint CVMP/CHMP ad-hoc expert group on the application of the 3Rs (replacement, reduction and refinement) in the regulatory testing of medicinal products (J 3RsWG)

No topics

6.2. Joint CHMP/CVMP/CMDh/CMDv Working Group on Active Substance Master File Procedures (ASMF WG)

No topics

6.3. Collaboration with other Scientific committees

6.3.1. PRAC report to CHMP

Chair: Sabine Straus

Summary of recommendations and advice of PRAC meeting held on 05-08 July 2021

Action: For information

The CHMP noted the summary of recommendations and advice.

6.3.2. Draft Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells

In October 2020, to account for inconsistencies in the product information of ATMPs containing genetically modified cells, the CAT, in agreement with the CAT EC representative and QRD group initiated a review of the QRD template to introduce additional wording and guidance specific to these products. Due to the extent of changes required, the work has culminated in the creation of a core SmPC, labelling and package leaflet for ATMPs containing genetically modified cells, to be read in conjunction with the SmPC guideline and QRD template.

The core SmPC has been agreed with CAT/QRD and EC and is brought to the CHMP for adoption prior to a 3-month external consultation.

Action: For adoption

CHMP adopted the Draft Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells for a 3-month public consultation with no further comments.

7. Regulatory / Organisational matters

7.1. Regulatory Issues / new legislation

7.1.1. Status update on the Companion Diagnostics (CDx) consultation working group

To provide a progress update on interactions of CHMP-CAT-EMA experts with Notified Bodies (NBs) to develop the NB consultation procedure on CDx suitability with EMA.

Action: For discussion

CHMP noted the progress on the interaction of CHMP-CAT-EMA experts with Notified Bodies (NBs) to develop the NB consultation procedure on CDx suitability with EMA. CHMP organisation/templates

7.1.2. CHMP learnings

Collection, discussion and recording of CHMP learnings.

CHMP: Outi Mäki-Ikola

Action: For discussion

CHMP discussed the modified learnings to include example of questions to applicants under different scenarios. CHMP members are invited to provide comments for any improvement on the wording of these example questions.

7.1.3. CHMP Survey on resource bottleneck

EMA will start a survey to NCAs to better understand the issues with finding rapporteurs for COVID-19 and Non-COVID products. The survey will be sent to the NCA resource contact points mid of July asking for responses by end of July. Each NCA will receive one link via the EU survey tool.

Action: For information

CHMP noted survey to NCA on resource bottleneck with no further comments.

7.1.4. Progress on CHMP Work Plan 2021

Update on the progress of the 2021 CHMP Work Plan

Action: For information

CHMP topic leads presented the progress on the development of various topics and activities currently included in the Work Plan. CHMP noted the progress of the CHMP Work Plan 2021.

8. Product development support

8.1. Scientific Advice Working Party (SAWP)

Chair: Anja Schiel

8.1.1. Appointment of CHMP peer review for SA

Action: For information

CHMP noted the appointment of CHMP peer review for Scientific Advice.

8.2. Innovation Task Force

8.2.1. ITF meeting

Meeting date: 12 July 2021

Action: For adoption

CHMP endorsed the meeting.

8.2.2. ITF meeting

Meeting date: 27 July 2021 (proposed)

Action: For adoption

CHMP endorsed the meeting.

9. Product related topics

9.1.1. Preview CHMP Plenary

CHMP: Harald Enzmann

Action: For information

The CHMP noted the update.

CHMP chair flagged some procedures for adoption in the upcoming plenary for which different views from committee members indicate possibly extended discussion. CHMP members involved or particularly interested in these procedures were encouraged to discuss in advance before the plenary meeting. Sending comments prior to the plenary meeting was encouraged as this will facilitate a structured discussion.

9.1.2. COVID-19 ongoing and upcoming procedures

List of currently ongoing and upcoming (imminently, i.e. expected within the next 2 months) applications for COVID-19 vaccines and therapeutics.

Action: For information

CHMP noted presentation on the status of currently COVID-19 ongoing and upcoming applications.

9.1.3. tanezumab - EMEA/H/C/005189

Treatment of moderate to severe chronic pain associated with osteoarthritis (OA) in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and/or an opioid is ineffective, not tolerated or inappropriate

Scope: Update on the status of this application.

Action: For discussion

CHMP was updated with the status of this application.

10. Any Other Business

10.1.1. Introduction of IRIS for Inspections: upcoming changes affecting documents tabled for CHMP

With the implementation of IRIS for inspections, planned to go live in Q3/Q4 2021, EMA's Inspections Office is making changes to the inspection-related documents tabled/circulated to CHMP.

Action: For information

CHMP was presented with the implementation of IRIS for inspections and how the change of system will affect the CHMP in terms of inspection-related documents tabled/circulated. CHMP noted the changes being implemented with IRIS.

10.1.2. Collaboration with HTA bodies – Report on the experience

EMA and the European Network for Health Technology Assessment (EUnetHTA) have recently published a report on their achievements since 2017 (Report on the implementation of the EMA-EUnetHTA work plan 2017–2021 (EMA/265469/2021)). The report covers the latest phase of an open and successful collaboration that began in 2010 and demonstrated the synergies between regulatory evaluation and health technology assessment (HTA) along the lifecycle of a medicine can be harnessed to speed up patients' access to innovative medicines. The positive experience over the past decade highlights the importance of a sustainable European cooperation between EMA and HTA bodies to facilitate cross-fertilisation and collaborative work on methodologies and products. A list of priority areas for future cooperation is currently being established.

Action: For information

CHMP noted the conclusions of the report on the implementation of the EMA-EUnetHTA work plan 2017 – 2021 (EMA/265469/2021). CHMP highlighted the importance on interactions with HTAs and its impact on the CHMP work; this will be even more relevant in the near future due to upcoming legislative proposal. CHMP invited more information on the upcoming legislative proposal on HTAs and welcome for further presentation at PROM whenever information is available.

10.1.3. CHMP strategic, review and learning meeting under the Portuguese presidency of the Council of the European Union

Presentations of the SRLM meeting held virtually on 27 May 2021 under the Portuguese presidency.

CHMP: Bruno Sepodes, Fatima Ventura

Action: For information

CHMP noted the availability of the presentation from the CHMP strategic, review and learning meeting under the Portuguese presidency of the Council of the European Union held remotely on 27th May 2021.

10.1.4. Call for interest for nomination of CHMP members to join temporary ad-hoc group on complex trials Q&A - call for experts

The European Commission (DG Santé B4) has initiated the development of a question and answer document on 'complex clinical trials' in collaboration with EMA and the clinical trials facilitation group (CTFG). A first draft is now available, spanning a large scope of topics (master protocols, Bayesian methodology, use of external control, biomarkers, safety, transparency and study integrity). As the next important step, the EC/EMA/CTFG drafting group is now looking for volunteers from the network to contribute to this first draft and subsequent activities expected to span over the rest of 2021, and possibly beyond. Interested members should express interest by 16 July 2021.

Action: For information

CHMP noted call for interest for nomination of CHMP members to join temporary ad-hoc group on complex trials Q&A.

11. List of Participants

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on the agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphy	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Ilko Getov	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Kirstine Moll Harboe	Alternate	Denmark	No interests declared	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantinos Markopoulos	Member	Greece	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting on	Covid Vaccines

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on the agenda for which restrictions apply
Martine Trauffler	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Bjorg Bolstad	Member	Norway	No restrictions applicable to this meeting	
Ingrid Wang	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on	Covid Vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No restrictions applicable to this meeting	
Nevenka Trsinar Brodt	Alternate	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Peter Mol	Expert - via Webex*	Netherlands	No interests declared	
Thomas Lang	Expert - via Webex*	Austria	No interests declared	
Nicolas Lee	Expert - via Webex*	Ireland	No restrictions applicable to this meeting	
Nora Cascante Estepa	Expert - via Webex*	Germany	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on the agenda for which restrictions apply
Irene Bachmann	Expert - via Webex*	Germany	No interests declared	
Carolien Versantvoort	Expert - via Webex*	Netherlands	No interests declared	
Christian B. (Kit) Roes	Expert - via Webex*	Netherlands	No restrictions applicable to this meeting	
Audrey Sultana	Expert - via Webex*	Malta	No interests declared	
Kristina Bech Jensen	Expert - via Webex*	Denmark	No interests declared	
Deirdre Mannion	Expert - via Webex*	Denmark	No restrictions applicable to this meeting	
Conception Gimenez Rebollo	Expert - via Webex*	Spain	No restrictions applicable to this meeting	
Maria Victoria Tudanca Pacios	Expert - via Webex*	Spain	No restrictions applicable to this meeting	
Meeting run with the help of EMA staff				

*Experts were evaluated against the product(s) they have been invited to talk about